Tonix Pharmaceuticals prices $20 million registered direct offering

Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced it entered into a securities purchase agreement with Point72 for a registered direct offering expected to raise approximately $20.0 million in gross proceeds.

The biotechnology company will sell 615,025 shares of common stock at $16.26 per share and pre-funded warrants to purchase up to 615,025 shares at $16.259 per warrant. The pre-funded warrant price equals the stock offering price minus the $0.001 exercise price per warrant.

The offering is expected to close on or about December 30, 2025, subject to customary closing conditions. TD Cowen serves as sole placement agent, while A.G.P./Alliance Global Partners acts as financial advisor.

Tonix stated it intends to use net proceeds to fund commercialization of its marketed products, development of its product pipeline, and general working capital purposes. The company markets FDA-approved TONMYA for fibromyalgia treatment and two acute migraine treatments: Zembrace SymTouch and Tosymra.

The offering is conducted under an effective shelf registration statement on Form S-3 previously filed with the Securities and Exchange Commission.

You May Also Be Interested In

• Singularity Future Technology closes $5M registered direct offering
• EShallGo closes $1.75M registered direct offering at $1 per share
• Kairos Pharma announces 1-for-7 reverse stock split